Andrea Osswald

Andrea Osswald

Auto-generated profile, based on publicly available information

Andrea Osswald

Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität, Ziemssenstraße 5, München 80336, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in EBioMedicine
Verified
Journal Article
Open access
LBLeah T. Braun
Leah T. Braun
AOAndrea Osswald
Andrea Osswald
SZStephanie Zopp
Stephanie Zopp
GRGerman Rubinstein
German Rubinstein
FVFrederick Vogel
Frederick Vogel
SWStefan A. Wudy
Stefan A. Wudy
Diagnosing Cushing's syndrome (CS) is highly complex. As the diagnostic potential of urinary steroid metabolome analysis by gas chromatography-mass spectrometry (GC-MS) in combination with systems biology has not yet been fully exploited, we studied a large cohort of patients with CS. We quantified daily urinary excretion rates of 36 steroid hormone metabolites. Applying cluster analysis, we investigated a control group and 168 patients: 44 with Cushing's disease (CD) (70% female), 18 with unilateral cortisol-producing adrenal adenoma (83% female), 13 with primary bilateral macronodular adrenal hyperplasia (PBMAH) (77% female), and 93 ruled-out CS (73% female). Cluster-Analysis delineated five urinary steroid metabotypes in CS. Metabotypes 1, 2 and 3 revealing average levels of cortisol and adrenal androgen metabolites included patients with exclusion of CS or and healthy controls. Metabotype 4 reflecting moderately elevated cortisol metabolites but decreased DHEA metabolites characterized the patients with unilateral adrenal CS and PBMAH. Metabotype 5 showing strong increases both in cortisol and DHEA metabolites, as well as overloaded enzymes of cortisol inactivation, was characteristic of CD patients. 11-oxygenated androgens were elevated in all patients with CS. The biomarkers THS, F, THF/THE, and (An + Et)/(11β-OH-An + 11β-OH-Et) correctly classified 97% of patients with CS and 95% of those without CS. An inverse relationship between 11-deoxygenated and 11-oxygenated androgens was typical for the ACTH independent (adrenal) forms of CS with an accuracy of 95%. GC-MS based urinary steroid metabotyping allows excellent identification of patients with endogenous CS and differentiation of its subtypes. The study was funded by the Else Kröner-Fresenius-Stiftung and the Eva-Luise-und-Horst-Köhler-Stiftung.

Verified
Journal Article
Open access
PDF file
SVsharmilee vetrivel
sharmilee vetrivel
RZRu Zhang
Ru Zhang
MEMareen Engel
Mareen Engel
AOAndrea Oßwald
Andrea Oßwald
DWDeepika Watts
Deepika Watts
ARAnna Riester
Anna Riester
MiRNAs are important epigenetic players with tissue- and disease-specific effects. In this study, our aim was to investigate the putative differential expression of miRNAs in adrenal tissues from different forms of Cushing’s syndrome (CS). For this, miRNA-based next-generation sequencing was performed in adrenal tissues taken from patients with ACTH-independent cortisol-producing adrenocortical adenomas (CPA), from patients with ACTH-dependent pituitary Cushing’s disease (CD) after bilateral adrenalectomy, and from control subjects. A confirmatory QPCR was also performed in adrenals from patients with other CS subtypes, such as primary bilateral macronodular hyperplasia and ectopic CS. Sequencing revealed significant differences in the miRNA profiles of CD and CPA. QPCR revealed the upregulated expression of miR-1247-5p in CPA and PBMAH (log2 fold change > 2.5, p < 0.05). MiR-379-5p was found to be upregulated in PBMAH and CD (log2 fold change > 1.8, p < 0.05). Analyses of miR-1247-5p and miR-379-5p expression in the adrenals of mice which had been exposed to short-term ACTH stimulation showed no influence on the adrenal miRNA expression profiles. For miRNA-specific target prediction, RNA-seq data from the adrenals of CPA, PBMAH, and control samples were analyzed with different bioinformatic platforms. The analyses revealed that both miR-1247-5p and miR-379-5p target specific genes in the WNT signaling pathway. In conclusion, this study identified distinct adrenal miRNAs as being associated with CS subtypes.

5 April 2021 in Endocrine
Verified
Journal Article
Open access
PDF file
EHElena Heger
Elena Heger
GRGerman Rubinstein
German Rubinstein
LBLeah T. Braun
Leah T. Braun
SZStephanie Zopp
Stephanie Zopp
JHJürgen Honegger
Jürgen Honegger
AOAndrea Oßwald
Andrea Oßwald
Purpose: Cushing’s syndrome (CS) can lead to structural changes in the brain and cognitive impairment, but chemosensory function has not been investigated yet. The aim was to analyze sense of smell and taste in patients with CS and explore the effect of therapy.Methods: The study cohort comprised 20 patients with florid CS treated between 2018 and 2020 in the outpatient clinic of the LMU Munich. We compared these 20 patients with CS to 40 healthy subjects matched for age, sex, and smoking status. Patients’ sense of smell and taste was examined at diagnosis and 3 months after successful therapeutic surgery leading to clinical and biochemical remission. Odor threshold, discrimination, and identification were measured with “Sniffin’ Sticks”, taste was measured with “Taste Strips”. Perceived sense of smell and taste was retrieved via a questionnaire.Results: Patients with florid CS had significantly reduced smell (total smell score 30.3 vs. 34.4,p < 0.0005) and taste scores (9.5 vs. 12.0,p < 0.0005) compared to controls and significantly more frequently hyposmia (55 vs. 2.5%,p < 0.0005), hypogeusia (40 vs. 0%,p < 0.0005), and self-reported chemosensory impairment (60 vs. 0%,p < 0.0005). Three months after successful surgery, CS patients showed significant improvement of odor threshold (8.1 vs. 7.0,p < 0.0005), odor discrimination (12.0 vs. 11.0,p = 0.003), total smell score (33.4 vs. 30.3,p < 0.0005), and taste (11.5 vs. 9.5,p = 0.003).Conclusions: Chemosensory dysfunction is a novel and clinically relevant feature of CS.

1 October 2014 in Cancer Research
Verified
Journal Article
Closed access
Fabio FauczFabio Faucz
Fabio Faucz
FBFelix Beuschlei
Felix Beuschlei
MFMartin Fassnacht
Martin Fassnacht
GAGuilaume Assie
Guilaume Assie
DCDavide Calebiro
Davide Calebiro
BABruno Allolio
Bruno Allolio
Corticotropin-independent Cushing's syndrome may be caused by tumors or hyperplasia of the adrenal cortex. Until now genetic alterations explain only a small fraction of cases. The observation that a subset of adrenal adenomas is characterized by abnormal PKA activity despite the absence of mutations in candidate genes suggested as yet unknown alterations in the cAMP/PKA signaling cascade in these tumors. The aim of this study was the analysis of the genetic basis of Cushing's syndrome in order to reveal the gene/s responsible for the disease. Exome sequencing was performed in ten cortisol-producing adenomas and recurrent mutations in candidate genes were evaluated in additional 171 patients with adrenocortical tumors. Genome-wide copy number analysis was performed in 35 patients with cortisol secreting bilateral hyperplasias. The effects of these genetic defects were studied both clinically and in vitro. Exome sequencing in 8/10 adenomas revealed somatic mutations in the PRKACA gene, which encodes the main catalytic subunit of cyclic AMP-dependent protein kinase (PKA) (c.617A>C in seven and c.595_596insCAC in one). Overall, PRKACA somatic mutations were identified in a total of 22/59 (37%) adenomas from patients with overt Cushing's syndrome while these mutations were not detectable in patients with subclinical hypercortisolism (n=40) or in other adrenal tumors (n=82). Among 35 patients with cortisol producing hyperplasias, 5 (with two patients as first degree relatives) carried germline copy number gain of the chromosome 19 region including the PRKACA gene. In vitro studies demonstrated impaired inhibition of the mutant PRKACA by the PKA regulatory subunit, while cells from patients with germline chromosomal gains showed increased protein levels; in both cases, PKA activity was increased. The present study shows that more than one third of cortisol-producing adenomas associated with overt Cushing syndrome harbor unique somatic mutations of the main cAMP-dependent kinase catalytic subunit, PRKACA resulting in constitutive PKA activation. While in these patients the mutation is present only in tumor cells, germline duplication of the PRKACA gene was identified in a group of patients with bilateral adrenal hyperplasias. This is the first report of genetic alterations of the catalytic subunit of PKA linked to human disease: Germline PRKACA duplications with bilateral adrenal hyperplasias and somatic PRKACA mutations with unilateral cortisol producing adrenal adenomas. Citation Format: Fabio R. Faucz, Felix Beuschlei, Martin Fassnacht, Guilaume Assie, Davide Calebiro, Constantine Stratakis, Andrea Osswald, Cristina L. Ronchi, Thomas Wieland, Silviu Sbiera, Katrin Schaak, Anett Schmittfull, Thomas Schwarzmayr, Olivia Barreau, Delphine Vezzosi, Marthe Rizk-Rabbin, Ulrike Zabel, Eva Szarek, Paraskevi Salpea, Antonella Forlino, Annalisa Vetro, Orsetta Zuffardi, Caroline Kisker, Susanne Diener, Thomas Meitinger, Martin J. Lohse, Martin Reincke, Jerome Bertherat, Tim M. Strom, Bruno Allolio. Constitutive activation of PRKACA in adrenal Cushing's syndrome. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-182. doi:10.1158/1538-7445.AM2014-LB-182